JP7672657B2 - 核酸脂質粒子ワクチン - Google Patents

核酸脂質粒子ワクチン Download PDF

Info

Publication number
JP7672657B2
JP7672657B2 JP2022530615A JP2022530615A JP7672657B2 JP 7672657 B2 JP7672657 B2 JP 7672657B2 JP 2022530615 A JP2022530615 A JP 2022530615A JP 2022530615 A JP2022530615 A JP 2022530615A JP 7672657 B2 JP7672657 B2 JP 7672657B2
Authority
JP
Japan
Prior art keywords
rbd
cov
mrna
sequence
sars
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022530615A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021251453A1 (https=
JPWO2021251453A5 (https=
Inventor
義裕 河岡
正樹 今井
誠也 山吉
健 石井
康司 小檜山
栄子 難波
竜也 岡
幸 戸塚
直 城内
宜郷 小野寺
文彦 武下
貴 鈴木
貴子 丹羽
誠 小泉
健介 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Sankyo Co Ltd
University of Tokyo NUC
Original Assignee
Daiichi Sankyo Co Ltd
University of Tokyo NUC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd, University of Tokyo NUC filed Critical Daiichi Sankyo Co Ltd
Publication of JPWO2021251453A1 publication Critical patent/JPWO2021251453A1/ja
Publication of JPWO2021251453A5 publication Critical patent/JPWO2021251453A5/ja
Priority to JP2025044691A priority Critical patent/JP2025094115A/ja
Application granted granted Critical
Publication of JP7672657B2 publication Critical patent/JP7672657B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/20011—Coronaviridae
    • C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2022530615A 2020-06-11 2021-06-10 核酸脂質粒子ワクチン Active JP7672657B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025044691A JP2025094115A (ja) 2020-06-11 2025-03-19 核酸脂質粒子ワクチン

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
JP2020101420 2020-06-11
JP2020101420 2020-06-11
JP2021033278 2021-03-03
JP2021033278 2021-03-03
PCT/JP2021/022057 WO2021251453A1 (ja) 2020-06-11 2021-06-10 核酸脂質粒子ワクチン

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025044691A Division JP2025094115A (ja) 2020-06-11 2025-03-19 核酸脂質粒子ワクチン

Publications (3)

Publication Number Publication Date
JPWO2021251453A1 JPWO2021251453A1 (https=) 2021-12-16
JPWO2021251453A5 JPWO2021251453A5 (https=) 2024-06-13
JP7672657B2 true JP7672657B2 (ja) 2025-05-08

Family

ID=78846062

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022530615A Active JP7672657B2 (ja) 2020-06-11 2021-06-10 核酸脂質粒子ワクチン
JP2025044691A Pending JP2025094115A (ja) 2020-06-11 2025-03-19 核酸脂質粒子ワクチン

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025044691A Pending JP2025094115A (ja) 2020-06-11 2025-03-19 核酸脂質粒子ワクチン

Country Status (7)

Country Link
US (1) US20230248819A1 (https=)
EP (1) EP4166158A4 (https=)
JP (2) JP7672657B2 (https=)
KR (1) KR20230024261A (https=)
CN (1) CN115605221A (https=)
TW (1) TWI907439B (https=)
WO (1) WO2021251453A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12409219B2 (en) 2020-06-30 2025-09-09 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and uses thereof
GB202119115D0 (en) * 2021-12-30 2022-02-16 Fondo Ricerca Medica S R I Vaccine
US20250109173A1 (en) * 2021-12-31 2025-04-03 Boost Biopharma, Inc. Recombinant polypeptides containing at least one immunogenic fragment and antibody fc region and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005253A1 (ja) 2013-07-08 2015-01-15 第一三共株式会社 新規脂質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL4023249T3 (pl) * 2014-04-23 2025-03-10 Modernatx, Inc. Szczepionki z kwasem nukleinowym
JP2020101420A (ja) 2018-12-21 2020-07-02 パナソニックＩｐマネジメント株式会社 透過度検知装置
CN110361853B (zh) 2019-08-16 2021-08-20 诚瑞光学(常州)股份有限公司 摄像光学镜头
US20210228707A1 (en) * 2020-01-28 2021-07-29 Modernatx, Inc. Coronavirus rna vaccines

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005253A1 (ja) 2013-07-08 2015-01-15 第一三共株式会社 新規脂質

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BioNTech，BNT162 COVID-19 Vaccine, Program Update，2020年04月，pp. 1-15，[retrieved on 2020.8.10], Retrieved from the Internet: <https://investors.biontech.de/static-files/398d9bd8-e2cb-49ca-9d6d-7dfd01c66b8a>
MCKAY, P.F. et al.，Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine induces equivalent preclinical antibody ti，bioRxiv，pp. 1-14，doi: https://doi.org/10.1101/2020.04.22.055608
WANG, F. et al.，An Evicence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development，Med Sci Monit，2020年05月，Vol. 26, Aritcle No. e924700，pp. 1-8，ISSN 1643-3750

Also Published As

Publication number Publication date
TWI907439B (zh) 2025-12-11
JP2025094115A (ja) 2025-06-24
EP4166158A1 (en) 2023-04-19
KR20230024261A (ko) 2023-02-20
JPWO2021251453A1 (https=) 2021-12-16
CN115605221A (zh) 2023-01-13
EP4166158A4 (en) 2025-07-16
TW202214296A (zh) 2022-04-16
US20230248819A1 (en) 2023-08-10
WO2021251453A1 (ja) 2021-12-16

Similar Documents

Publication Publication Date Title
Liu et al. A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs
JP2024503698A (ja) 変異型株ベースのコロナウイルスワクチン
JP2025094115A (ja) 核酸脂質粒子ワクチン
CN110381994B (zh) 用于诱导针对寨卡病毒的免疫应答的核苷修饰的rna
WO2021159130A2 (en) Coronavirus rna vaccines and methods of use
JP2023513073A (ja) 呼吸器系ウイルス免疫化組成物
US11028397B2 (en) 5′-triphosphate oligoribonucleotides
TW202206097A (zh) 冠狀病毒抗原組成物及其用途
EP4059515A1 (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna
JP2026503718A (ja) エプスタイン・バーウイルスｍＲＮＡワクチン
EP4404962A2 (en) Piv5-based coronavirus vaccines and methods of use thereof
JPWO2022244801A5 (https=)
TW202500750A (zh) 用於治療痤瘡的組成物
HK40087016A (en) Nucleic acid lipid particle vaccine
CA3130956A1 (en) Novel vaccine effective to prevent infection by sars-cov variants
TW202313101A (zh) 流感病毒核酸脂質粒子疫苗
CN116710557A (zh) 编码sars-cov-2抗原的优化核苷酸序列
WO2025149032A1 (en) Respiratory syncytial virus vaccine compositions and their use
US20240316169A1 (en) Utilization of antibodies to shape antibody responses to an antigen
HK40074627A (en) Nucleic acid lipid particle vaccine encapsulating hpv mrna
WO2025027579A2 (en) Rna compositions targeting hiv
WO2025225716A1 (ja) Ｓｆｔｓｖ核酸脂質粒子ワクチン
JP2024537847A (ja) ＣＯＶＩＤ１９ ｍＲＮＡワクチン
CN118632708A (zh) 基于piv5的冠状病毒疫苗及其使用方法
KR20260052229A (ko) 백신 보조제

Legal Events

Date Code Title Description
RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20220912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220912

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240605

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240605

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20240605

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240703

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240902

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250115

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250319

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250402

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250414

R150 Certificate of patent or registration of utility model

Ref document number: 7672657

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150